High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4(+) and CD8(+) neoantigen-specific T cells to promote antitumor immunity

BACKGROUND: Immunization with tumor neoantigens is a promising vaccine approach to promote antitumor immunity due to their high immunogenicity, lack of expression in normal tissue, and preferential induction of tumor neoantigen-specific T cells, which are central mediators of the anti-cancer respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez, Rosmely, LaPorte, Kathryn M, Hsiung, Sunnie, Santos Savio, Alicia, Malek, Thomas R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413969/
https://www.ncbi.nlm.nih.gov/pubmed/34475132
http://dx.doi.org/10.1136/jitc-2021-002865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413969/
https://www.ncbi.nlm.nih.gov/pubmed/34475132
http://dx.doi.org/10.1136/jitc-2021-002865

Ejemplares similares